# Competitive Landscape Analyst - Comprehensive Test Suite

**Purpose**: Test all 100+ capabilities of the competitive-landscape-analyst agent across 12 capability domains.

**Format**: "The [Memorable Name]" - Each test category has a memorable theme to make testing memorable and comprehensive.

**Test Status**: üî¥ Not Run | üü° Running | üü¢ Passed | ‚ùå Failed

---

## Test Categories Overview

| Category | Theme | Test Count | Status |
|----------|-------|------------|--------|
| 1. Pipeline Intelligence | "The Prospector" | 8 tests | üî¥ |
| 2. Clinical Trial Monitoring | "The Hawk" | 8 tests | üî¥ |
| 3. Financial Analysis | "The Banker" | 8 tests | üî¥ |
| 4. Strategic Synthesis | "The Chess Master" | 8 tests | üî¥ |
| 5. Data Collection | "The Librarian" | 8 tests | üî¥ |
| 6. Analytical Frameworks | "The Mathematician" | 8 tests | üî¥ |
| 7. Reporting & Communication | "The Journalist" | 8 tests | üî¥ |
| 8. Technology & Automation | "The Engineer" | 8 tests | üî¥ |
| 9. Therapeutic Area Specialization | "The Specialist" | 8 tests | üî¥ |
| 10. Partnership & Deal Intelligence | "The Deal Maker" | 8 tests | üî¥ |
| 11. Risk Assessment | "The Oracle" | 8 tests | üî¥ |
| 12. Action Planning | "The General" | 8 tests | üî¥ |

**Total Tests**: 96

---

## Category 1: Pipeline Intelligence & Tracking ("The Prospector")

*"Prospecting for gold in the R&D pipeline"*

### Test 1.1: Real-Time Pipeline Monitoring
**Query**: "What are the latest KRAS G12D inhibitor programs in Phase 2?"

**Tests**:
- IND filing identification
- Trial initiation detection
- Phase progression tracking

**Expected Skills**:
- `get_kras_inhibitor_trials` (existing)
- Filtering for G12D mutation + Phase 2

**Expected Output**:
- List of active Phase 2 G12D programs
- Company names and trial NCT IDs
- Enrollment timelines

**Status**: üî¥

---

### Test 1.2: Disease Area Mapping
**Query**: "Map all PD-1/PD-L1 checkpoint inhibitor programs across solid tumors"

**Tests**:
- Mechanism of action mapping
- Indication grouping
- Competitor portfolio visualization

**Expected Skills**:
- New skill: `get_pd1_checkpoint_trials`
- Multi-indication aggregation

**Expected Output**:
- Matrix of companies √ó indications
- Trial count by indication
- Development stage distribution

**Status**: üî¥

---

### Test 1.3: Development Timeline Prediction
**Query**: "Predict market entry timing for GLP-1 competitors Eli Lilly and Novo Nordisk based on their Phase 3 timelines"

**Tests**:
- Historical success rate analysis
- Timeline prediction modeling
- Company-specific pattern recognition

**Expected Skills**:
- `get_glp1_trials` (existing)
- Company filtering
- Phase 3 enrollment analysis

**Expected Output**:
- Predicted approval dates (ranges)
- Confidence intervals
- Key milestone dates

**Status**: üî¥

---

### Test 1.4: Orphan Drug Designation Tracking
**Query**: "Identify all rare disease programs with orphan designation in neurodegenerative diseases"

**Tests**:
- Orphan designation detection
- Rare disease categorization
- Regulatory advantage assessment

**Expected Skills**:
- New skill: `get_neurodegen_orphan_trials`
- Orphan status filtering

**Expected Output**:
- List of orphan programs
- Disease targets (prevalence <200k)
- Market exclusivity windows

**Status**: üî¥

---

### Test 1.5: Biomarker Strategy Analysis
**Query**: "Analyze biomarker-driven patient selection strategies in EGFR+ lung cancer trials"

**Tests**:
- Biomarker identification
- Patient stratification patterns
- Companion diagnostic tracking

**Expected Skills**:
- New skill: `get_egfr_lung_cancer_trials`
- Biomarker extraction from protocols

**Expected Output**:
- Biomarker usage frequency
- Selection criteria comparison
- CDx development programs

**Status**: üî¥

---

### Test 1.6: Combination Therapy Tracking
**Query**: "Track all BRAF inhibitor + MEK inhibitor combination trials in melanoma"

**Tests**:
- Combination regimen identification
- Synergy hypothesis tracking
- Safety profile monitoring

**Expected Skills**:
- `get_braf_inhibitor_trials` (existing)
- Combination filtering (BRAF+MEK)

**Expected Output**:
- List of BRAF+MEK combos
- Comparison to monotherapy
- Toxicity patterns

**Status**: üî¥

---

### Test 1.7: Pipeline Attrition Analysis
**Query**: "Analyze attrition patterns in Alzheimer's disease programs over the last 5 years"

**Tests**:
- Terminated trial identification
- Failure reason extraction
- Success rate calculation

**Expected Skills**:
- New skill: `get_alzheimers_terminated_trials`
- Historical data (2020-2025)

**Expected Output**:
- Attrition rate by phase
- Common failure reasons
- Surviving programs

**Status**: üî¥

---

### Test 1.8: Platform Technology Tracking
**Query**: "Identify all mRNA platform technology programs in infectious disease vaccines"

**Tests**:
- Platform technology categorization
- Modality tracking (mRNA, DNA, viral vector)
- Technology maturity assessment

**Expected Skills**:
- New skill: `get_mrna_vaccine_trials`
- Platform technology filtering

**Expected Output**:
- mRNA programs by company
- Target diseases
- Development stage

**Status**: üî¥

---

## Category 2: Clinical Trial Monitoring & Analysis ("The Hawk")

*"Eyes on every trial, 24/7 surveillance"*

### Test 2.1: ClinicalTrials.gov Surveillance
**Query**: "Monitor all COVID-19 antiviral trials that started recruiting in the last 30 days"

**Tests**:
- Recent trial detection
- Recruitment status tracking
- Global registry monitoring

**Expected Skills**:
- New skill: `get_covid_antiviral_trials_recent`
- Date filtering (last 30 days)

**Expected Output**:
- List of new trials
- Sponsor companies
- Geographic locations

**Status**: üî¥

---

### Test 2.2: Trial Design Comparison
**Query**: "Compare primary endpoints across all Phase 3 heart failure trials"

**Tests**:
- Endpoint extraction
- Design differentiation analysis
- Competitive positioning

**Expected Skills**:
- New skill: `get_heart_failure_phase3_trials`
- Endpoint parsing

**Expected Output**:
- Table of trials √ó endpoints
- Unique endpoint strategies
- Standard vs novel endpoints

**Status**: üî¥

---

### Test 2.3: Enrollment Rate Tracking
**Query**: "Track enrollment progress for all recruiting CAR-T cell therapy trials"

**Tests**:
- Enrollment velocity calculation
- Completion timeline prediction
- Site performance analysis

**Expected Skills**:
- New skill: `get_cart_trials_recruiting`
- Enrollment data extraction

**Expected Output**:
- Current enrollment numbers
- Target enrollment
- Estimated completion dates

**Status**: üî¥

---

### Test 2.4: Protocol Amendment Analysis
**Query**: "Identify recent protocol amendments in Duchenne muscular dystrophy trials and their strategic implications"

**Tests**:
- Amendment detection
- Change impact assessment
- Strategic signal identification

**Expected Skills**:
- New skill: `get_dmd_trials`
- Amendment tracking

**Expected Output**:
- List of amended trials
- Amendment reasons (efficacy/safety/enrollment)
- Competitive implications

**Status**: üî¥

---

### Test 2.5: Site Selection Strategy
**Query**: "Analyze geographic site distribution for obesity trials in the US vs Europe"

**Tests**:
- Site location mapping
- Geographic strategy comparison
- Regional enrollment patterns

**Expected Skills**:
- `get_us_phase3_obesity_recruiting_trials` (existing)
- New skill: `get_eu_obesity_trials`

**Expected Output**:
- US vs EU site counts
- State/country breakdown
- Strategic site concentration

**Status**: üî¥

---

### Test 2.6: Interim Data Release Monitoring
**Query**: "Track all planned interim analyses for PD-1 combination trials with data readout in 2026"

**Tests**:
- Interim analysis identification
- Data release timeline tracking
- Conference presentation monitoring

**Expected Skills**:
- New skill: `get_pd1_combo_trials_2026`
- Interim analysis extraction

**Expected Output**:
- List of trials with interim analyses
- Planned readout dates
- Conference presentation schedules

**Status**: üî¥

---

### Test 2.7: Success Probability Modeling
**Query**: "Calculate success probability for all Phase 2 oncology trials based on trial characteristics"

**Tests**:
- Probability of success (PoS) modeling
- Trial characteristic scoring
- Historical benchmark comparison

**Expected Skills**:
- New skill: `get_phase2_oncology_trials`
- PoS calculation framework

**Expected Output**:
- PoS scores by trial
- High-confidence programs
- Risk factors identified

**Status**: üî¥

---

### Test 2.8: Adaptive Trial Design Tracking
**Query**: "Identify all adaptive design trials in rare diseases and analyze their flexibility strategies"

**Tests**:
- Adaptive design identification
- Flexibility mechanism analysis
- Sample size re-estimation tracking

**Expected Skills**:
- New skill: `get_rare_disease_adaptive_trials`
- Design feature extraction

**Expected Output**:
- List of adaptive trials
- Design flexibility types
- Regulatory acceptance patterns

**Status**: üî¥

---

## Category 3: Financial & Investment Analysis ("The Banker")

*"Follow the money, find the priorities"*

### Test 3.1: R&D Spending Analysis
**Query**: "Analyze Pfizer's R&D spending by therapeutic area for 2023-2024"

**Tests**:
- SEC filing analysis (10-K, 10-Q)
- R&D allocation by TA
- Year-over-year comparison

**Expected Skills**:
- New skill: `get_pfizer_sec_rd_spending`
- Financial data extraction

**Expected Output**:
- R&D spend by TA (table)
- YoY growth rates
- Priority area identification

**Status**: üî¥

---

### Test 3.2: Resource Allocation Patterns
**Query**: "Compare Gilead's oncology vs infectious disease R&D investment trends over 5 years"

**Tests**:
- Multi-year trend analysis
- Portfolio priority shifts
- Strategic pivot identification

**Expected Skills**:
- New skill: `get_gilead_sec_portfolio_analysis`
- Historical data (2020-2025)

**Expected Output**:
- Investment trends by TA
- Portfolio shift timeline
- Strategic implications

**Status**: üî¥

---

### Test 3.3: Venture Funding Tracking
**Query**: "Track all Series A/B funding rounds for gene therapy startups in 2024-2025"

**Tests**:
- Venture funding detection
- Startup identification
- Investment trend analysis

**Expected Skills**:
- New skill: `get_gene_therapy_funding`
- Financial database integration

**Expected Output**:
- List of funded companies
- Funding amounts
- Lead investors

**Status**: üî¥

---

### Test 3.4: Market Cap Impact Analysis
**Query**: "Assess market cap impact of Eli Lilly's recent GLP-1 Phase 3 results announcement"

**Tests**:
- Stock price impact modeling
- Pipeline event correlation
- Investor sentiment analysis

**Expected Skills**:
- New skill: `get_eli_lilly_stock_events`
- Market data integration

**Expected Output**:
- Pre/post announcement market cap
- Percentage change
- Analyst reactions

**Status**: üî¥

---

### Test 3.5: Development Cost Estimation
**Query**: "Estimate total development cost for bringing a Phase 2 autoimmune drug to market"

**Tests**:
- Cost per phase estimation
- Clinical trial budget modeling
- Regulatory cost inclusion

**Expected Skills**:
- Cost modeling framework
- Historical cost benchmarks

**Expected Output**:
- Cost breakdown by phase
- Total estimated cost (range)
- Success-adjusted NPV

**Status**: üî¥

---

### Test 3.6: Burn Rate Analysis
**Query**: "Calculate burn rate and runway for all publicly traded CAR-T companies"

**Tests**:
- Cash position analysis
- Quarterly burn rate calculation
- Runway estimation

**Expected Skills**:
- New skill: `get_cart_companies_financials`
- SEC cash flow analysis

**Expected Output**:
- Current cash positions
- Quarterly burn rates
- Months of runway remaining

**Status**: üî¥

---

### Test 3.7: Portfolio Valuation
**Query**: "Value Amgen's biosimilar portfolio using risk-adjusted NPV methodology"

**Tests**:
- NPV calculation
- Risk adjustment (PoS)
- Portfolio total valuation

**Expected Skills**:
- New skill: `get_amgen_biosimilar_portfolio`
- rNPV modeling

**Expected Output**:
- Individual asset valuations
- Total portfolio value
- Key value drivers

**Status**: üî¥

---

### Test 3.8: Analyst Consensus Tracking
**Query**: "Monitor analyst consensus forecasts for Moderna's revenue growth 2025-2030"

**Tests**:
- Analyst report aggregation
- Consensus forecast extraction
- Forecast dispersion analysis

**Expected Skills**:
- New skill: `get_moderna_analyst_consensus`
- Financial data integration

**Expected Output**:
- Consensus revenue forecasts
- High/low estimates
- Earnings estimate ranges

**Status**: üî¥

---

## Category 4: Strategic Intelligence Synthesis ("The Chess Master")

*"Thinking 3 moves ahead"*

### Test 4.1: Competitor Capability Mapping
**Query**: "Map Regeneron's antibody engineering capabilities and assess their competitive advantage in immunology"

**Tests**:
- Capability identification
- Technology platform assessment
- Competitive advantage scoring

**Expected Skills**:
- New skill: `get_regeneron_antibody_portfolio`
- Technology analysis

**Expected Output**:
- Platform capabilities matrix
- Competitive differentiation
- Strategic advantages

**Status**: üî¥

---

### Test 4.2: Speed-to-Market Analysis
**Query**: "Predict which companies will reach market first with KRAS G12D inhibitors and analyze their competitive positioning"

**Tests**:
- Development timeline modeling
- First-mover advantage assessment
- Launch sequence prediction

**Expected Skills**:
- `get_kras_inhibitor_trials` (existing)
- Timeline prediction model

**Expected Output**:
- Predicted launch order
- Time-to-market estimates
- First-mover advantage analysis

**Status**: üî¥

---

### Test 4.3: Portfolio Gap Identification
**Query**: "Identify gaps in Bristol Myers Squibb's cardiovascular portfolio relative to competitors"

**Tests**:
- Portfolio mapping
- Competitive gap analysis
- White space identification

**Expected Skills**:
- New skill: `get_bms_cardio_portfolio`
- Competitor portfolio comparison

**Expected Output**:
- Gap analysis matrix
- White space opportunities
- Acquisition target profiles

**Status**: üî¥

---

### Test 4.4: Partnership Pattern Recognition
**Query**: "Analyze Merck's partnership patterns in oncology over the last 10 years and predict next moves"

**Tests**:
- Historical partnership analysis
- Pattern identification
- Future partnership prediction

**Expected Skills**:
- New skill: `get_merck_oncology_partnerships`
- Pattern recognition

**Expected Output**:
- Partnership timeline
- Deal structure patterns
- Predicted next targets

**Status**: üî¥

---

### Test 4.5: Regulatory Strategy Comparison
**Query**: "Compare regulatory approval strategies for biosimilars between Amgen, Pfizer, and Sandoz"

**Tests**:
- Regulatory pathway analysis
- Filing strategy comparison
- Approval success rates

**Expected Skills**:
- New skill: `get_biosimilar_regulatory_strategies`
- Multi-company comparison

**Expected Output**:
- Strategy comparison matrix
- Success rate by strategy
- Best practices identified

**Status**: üî¥

---

### Test 4.6: Market Entry Sequencing
**Query**: "Analyze geographic market entry sequencing for GLP-1 obesity drugs and recommend optimal strategy"

**Tests**:
- Launch sequence analysis
- Market prioritization
- Revenue optimization

**Expected Skills**:
- `get_glp1_fda_drugs` (existing)
- Geographic expansion tracking

**Expected Output**:
- Market entry timeline
- Priority markets (US, EU, China)
- Revenue impact by sequence

**Status**: üî¥

---

### Test 4.7: Competitive Response Scenarios
**Query**: "Model competitive responses if Novo Nordisk launches oral GLP-1 before Eli Lilly"

**Tests**:
- Scenario modeling
- Response strategy development
- Impact assessment

**Expected Skills**:
- `get_glp1_trials` (existing)
- Scenario framework

**Expected Output**:
- 3-5 response scenarios
- Probability-weighted outcomes
- Recommended countermeasures

**Status**: üî¥

---

### Test 4.8: Technology Platform Assessment
**Query**: "Assess BioNTech's mRNA platform competitiveness vs Moderna and CureVac across indications"

**Tests**:
- Platform capability comparison
- Cross-indication applicability
- Technology maturity scoring

**Expected Skills**:
- New skill: `get_mrna_platform_comparison`
- Multi-company assessment

**Expected Output**:
- Platform comparison matrix
- Indication applicability
- Competitive advantages

**Status**: üî¥

---

## Category 5: Data Collection & Source Management ("The Librarian")

*"Every source, every signal, every data point"*

### Test 5.1: Multi-Source Web Scraping
**Query**: "Aggregate all press releases from top 10 pharma companies mentioning 'Phase 3 initiation' in Q4 2024"

**Tests**:
- Web scraping automation
- Company website monitoring
- Press release extraction

**Expected Skills**:
- Web scraping capability
- News aggregation

**Expected Output**:
- Aggregated press releases
- Phase 3 initiations by company
- Timeline of announcements

**Status**: üî¥

---

### Test 5.2: SEC Filing Review
**Query**: "Extract all M&A mentions from biotech company 10-K filings in 2024"

**Tests**:
- SEC EDGAR integration
- M&A keyword extraction
- Strategic intent analysis

**Expected Skills**:
- New skill: `get_biotech_sec_ma_mentions`
- Text mining

**Expected Output**:
- List of companies with M&A mentions
- Specific language used
- Strategic signals

**Status**: üî¥

---

### Test 5.3: Conference Presentation Monitoring
**Query**: "Track all ASCO 2025 presentations for PD-1/PD-L1 combination therapies"

**Tests**:
- Conference abstract monitoring
- Presentation scheduling
- Data release anticipation

**Expected Skills**:
- New skill: `get_asco_2025_pd1_presentations`
- Conference database integration

**Expected Output**:
- List of presentations
- Presentation dates/times
- Company sponsors

**Status**: üî¥

---

### Test 5.4: Patent Database Searching
**Query**: "Search USPTO and Google Patents for CRISPR gene editing patents filed by Editas Medicine in 2023-2024"

**Tests**:
- USPTO and Google Patents BigQuery integration
- International patent coverage (11 countries)
- Freedom-to-operate analysis
- IP landscape mapping

**Expected Skills**:
- New skill: `get_editas_crispr_patents`
- Uses: `google_search_by_assignee()` (existing)
- Uses: `ppubs_search_patents()` (existing)

**Expected Output**:
- US patents from USPTO
- International patents from Google Patents (US, EP, WO, JP, etc.)
- Patent claims summary
- IP protection timeline

**Status**: üü¢ (Patent MCP fully operational with pagination)

---

### Test 5.4b: Large-Scale Patent Portfolio Retrieval (Pagination)
**Query**: "Retrieve complete patent portfolio for Novo Nordisk (1000+ patents) using pagination"

**Tests**:
- Pagination implementation (offset parameter)
- Large result set handling (> 500 patents)
- Multi-batch aggregation
- Data completeness verification

**Expected Skills**:
- Uses: `google_search_by_assignee()` with pagination (existing)
- Pagination loop implementation

**Expected Output**:
- Complete patent portfolio (1000+ patents)
- No duplicate patents
- Batch retrieval summary (e.g., "Retrieved 1000 patents in 2 batches")
- Filing trend analysis

**Status**: üü¢ (Pagination tested successfully - 1000 Novo Nordisk patents retrieved)

---

### Test 5.5: Social Media Surveillance
**Query**: "Monitor Twitter/X mentions of 'clinical hold' across all biotech companies in real-time"

**Tests**:
- Social media monitoring
- Sentiment analysis
- Early warning detection

**Expected Skills**:
- Social listening capability
- Sentiment scoring

**Expected Output**:
- Clinical hold mentions
- Companies affected
- Sentiment trends

**Status**: üî¥

---

### Test 5.6: KOL Insight Capture
**Query**: "Identify top 10 key opinion leaders in CAR-T therapy and track their recent publications"

**Tests**:
- KOL identification
- Publication tracking (PubMed)
- Influence scoring

**Expected Skills**:
- New skill: `get_cart_kols`
- PubMed integration

**Expected Output**:
- KOL list with affiliations
- Recent publications (2024-2025)
- Influence metrics

**Status**: üî¥

---

### Test 5.7: Industry Database Integration
**Query**: "Integrate Cortellis data for all Phase 2+ inflammatory bowel disease programs"

**Tests**:
- Third-party database integration
- Data normalization
- Enrichment workflows

**Expected Skills**:
- External database API
- Data integration

**Expected Output**:
- IBD program list
- Enriched with Cortellis data
- Standardized format

**Status**: üî¥

---

### Test 5.8: Primary Research Coordination
**Query**: "Design survey for oncologists on unmet needs in NSCLC to inform competitive strategy"

**Tests**:
- Primary research design
- Expert network coordination
- Insight synthesis

**Expected Skills**:
- Survey design framework
- Expert network access

**Expected Output**:
- Survey questionnaire
- Target expert list
- Analysis framework

**Status**: üî¥

---

## Category 6: Analytical Frameworks & Modeling ("The Mathematician")

*"Data without analysis is just noise"*

### Test 6.1: Competitive Positioning Matrix
**Query**: "Create competitive positioning matrix for all CDK4/6 inhibitors by efficacy and safety"

**Tests**:
- 2D positioning visualization
- Efficacy/safety scoring
- Competitive clustering

**Expected Skills**:
- New skill: `get_cdk46_inhibitor_data`
- Matrix framework

**Expected Output**:
- 2D matrix visualization
- Competitor positioning
- Strategic quadrants

**Status**: üî¥

---

### Test 6.2: Pipeline Overlap Analysis
**Query**: "Analyze pipeline overlap between AbbVie and Johnson & Johnson in immunology"

**Tests**:
- Portfolio comparison
- Overlap quantification
- Head-to-head identification

**Expected Skills**:
- New skill: `get_abbvie_jnj_immunology_portfolios`
- Overlap scoring

**Expected Output**:
- Overlap matrix
- Direct competitor pairs
- White space opportunities

**Status**: üî¥

---

### Test 6.3: Time-to-Market Modeling
**Query**: "Model time-to-market for all Phase 2 diabetes drugs with probability-adjusted timelines"

**Tests**:
- Monte Carlo simulation
- PoS adjustment
- Timeline distribution

**Expected Skills**:
- New skill: `get_phase2_diabetes_drugs`
- Probabilistic modeling

**Expected Output**:
- Predicted approval dates (P10, P50, P90)
- Confidence intervals
- Risk-adjusted timelines

**Status**: üî¥

---

### Test 6.4: Market Share Impact Assessment
**Query**: "Model market share impact if Novo Nordisk's oral GLP-1 captures 30% of new patients"

**Tests**:
- Market dynamics modeling
- Share shift simulation
- Revenue impact calculation

**Expected Skills**:
- Market modeling framework
- Share dynamics

**Expected Output**:
- Share shift scenarios
- Revenue impact by competitor
- Strategic implications

**Status**: üî¥

---

### Test 6.5: SWOT Analysis Automation
**Query**: "Generate automated SWOT analysis for Vertex Pharmaceuticals' cystic fibrosis franchise"

**Tests**:
- SWOT framework application
- Multi-source data synthesis
- Strategic insight generation

**Expected Skills**:
- New skill: `get_vertex_cf_portfolio`
- SWOT automation

**Expected Output**:
- Strengths (4-6 points)
- Weaknesses (4-6 points)
- Opportunities (4-6 points)
- Threats (4-6 points)

**Status**: üî¥

---

### Test 6.6: Porter's Five Forces Analysis
**Query**: "Apply Porter's Five Forces framework to analyze competitive intensity in oncology immuno-oncology"

**Tests**:
- Five Forces scoring
- Competitive intensity assessment
- Attractiveness evaluation

**Expected Skills**:
- Porter's framework
- Market structure analysis

**Expected Output**:
- Five Forces scores (1-5 scale)
- Overall attractiveness rating
- Strategic implications

**Status**: üî¥

---

### Test 6.7: Game Theory Modeling
**Query**: "Model competitive response game theory for pricing decisions in biosimilar market"

**Tests**:
- Nash equilibrium calculation
- Strategy payoff matrix
- Optimal strategy identification

**Expected Skills**:
- Game theory framework
- Payoff modeling

**Expected Output**:
- Payoff matrix
- Equilibrium strategies
- Recommended actions

**Status**: üî¥

---

### Test 6.8: Machine Learning Pattern Recognition
**Query**: "Use ML to identify patterns in clinical trial failures across oncology programs 2020-2025"

**Tests**:
- ML model training
- Pattern extraction
- Predictive feature identification

**Expected Skills**:
- ML modeling capability
- Historical failure data

**Expected Output**:
- Key failure predictors
- Pattern clusters
- Predictive accuracy metrics

**Status**: üî¥

---

## Category 7: Reporting & Communication ("The Journalist")

*"If it's not communicated, it didn't happen"*

### Test 7.1: Executive Dashboard Creation
**Query**: "Create real-time executive dashboard for cell therapy competitive landscape"

**Tests**:
- Dashboard design
- Real-time data integration
- KPI visualization

**Expected Skills**:
- New skill: `get_cell_therapy_dashboard_data`
- Visualization framework

**Expected Output**:
- Dashboard mockup/spec
- KPI definitions
- Update frequency

**Status**: üî¥

---

### Test 7.2: Competitive Alert System
**Query**: "Set up automated alerts for any KRAS inhibitor Phase 3 trial initiation"

**Tests**:
- Alert trigger definition
- Monitoring automation
- Notification workflow

**Expected Skills**:
- Alert system design
- Monitoring infrastructure

**Expected Output**:
- Alert rule specification
- Notification channels
- Escalation procedures

**Status**: üî¥

---

### Test 7.3: Weekly Pipeline Newsletter
**Query**: "Generate weekly competitive intelligence newsletter for week of January 20, 2025"

**Tests**:
- News aggregation
- Prioritization logic
- Newsletter formatting

**Expected Skills**:
- News aggregation
- Content curation

**Expected Output**:
- Newsletter content (500-800 words)
- Top 5 developments
- Strategic implications

**Status**: üî¥

---

### Test 7.4: Ad-Hoc Deep Dive Report
**Query**: "Generate comprehensive competitive deep dive on [therapeutic area]"

**Tests**:
- Full report generation
- Multi-source synthesis (trials + FDA + patents + financials)
- Strategic recommendations

**Expected Skills**:
- Multi-source data collection skills
- Report generation

**Expected Output**:
- 4000-6000 word report
- YAML frontmatter
- Actionable recommendations

**Status**: üü¢ (6 competitive landscape reports created)

**Existing Reports**:
- Eli Lilly's $1 Trillion Path (GLP-1 obesity market)
- Obesity Drug Market Intelligence (comprehensive competitive analysis)
- CAR-T Cell Therapy Strategic Landscape
- Alzheimer's Beyond Amyloid Strategic Landscape
- Precision Oncology CDx Co-development Strategies
- US-China Oncology Clinical Development Strategy

---

### Test 7.5: Visual Pipeline Timeline
**Query**: "Create visual timeline of all Alzheimer's disease programs from Phase 1 to approval"

**Tests**:
- Timeline visualization
- Milestone mapping
- Gantt chart creation

**Expected Skills**:
- New skill: `get_alzheimers_pipeline_timeline`
- Visualization design

**Expected Output**:
- Timeline specification
- Milestone markers
- Critical path identification

**Status**: üî¥

---

### Test 7.6: Threat & Opportunity Report
**Query**: "Identify top 3 competitive threats and top 3 opportunities in rare disease space"

**Tests**:
- Threat identification
- Opportunity assessment
- Prioritization logic

**Expected Skills**:
- Multi-disease scanning
- Risk/opportunity scoring

**Expected Output**:
- Top 3 threats (with severity)
- Top 3 opportunities (with attractiveness)
- Strategic recommendations

**Status**: üî¥

---

### Test 7.7: Strategic Recommendation Prioritization
**Query**: "Prioritize 10 BD opportunities in neurology based on strategic fit, timing, and feasibility"

**Tests**:
- Multi-criteria scoring
- Prioritization framework
- Recommendation ranking

**Expected Skills**:
- Scoring framework
- Decision criteria

**Expected Output**:
- Ranked opportunity list
- Score breakdown
- Action timeline

**Status**: üî¥

---

### Test 7.8: Board-Ready Presentation
**Query**: "Create board-ready presentation on competitive landscape in diabetes market"

**Tests**:
- Executive summary creation
- Visual design
- Key message hierarchy

**Expected Skills**:
- Presentation design
- Executive communication

**Expected Output**:
- Presentation outline (15-20 slides)
- Key messages
- Visual specifications

**Status**: üî¥

---

## Category 8: Technology & Automation Tools ("The Engineer")

*"Automate everything, analyze anything"*

### Test 8.1: NLP Document Analysis
**Query**: "Use NLP to extract mechanism of action from all Phase 2 oncology trial protocols"

**Tests**:
- NLP text extraction
- MoA classification
- Automated categorization

**Expected Skills**:
- NLP capability
- Protocol access

**Expected Output**:
- MoA taxonomy
- Trial classification
- Confidence scores

**Status**: üî¥

---

### Test 8.2: Clinical Trial Database API Integration
**Query**: "Integrate ClinicalTrials.gov API for automated daily updates of recruiting trials"

**Tests**:
- API integration
- Automated scheduling
- Incremental updates

**Expected Skills**:
- `ct_gov_mcp` (existing - fully operational)
- Automation framework

**Expected Output**:
- Integration specification
- Update schedule
- Change detection logic

**Status**: üü¢ (All 12 MCP servers operational: CT.gov, FDA, PubMed, USPTO/Google Patents, SEC, WHO, NLM Codes, CMS, Data Commons, Open Targets, PubChem, Financial Markets)

---

### Test 8.3: Automated Alert System
**Query**: "Build automated alert system for competitor pipeline milestones (FDA submissions, approvals, failures)"

**Tests**:
- Event detection
- Alert triggering
- Multi-channel notification

**Expected Skills**:
- Event monitoring
- Alert infrastructure

**Expected Output**:
- Alert rule engine
- Notification channels
- Escalation logic

**Status**: üî¥

---

### Test 8.4: ML Success Prediction
**Query**: "Train ML model to predict Phase 2 to Phase 3 success probability based on trial characteristics"

**Tests**:
- Feature engineering
- Model training
- Prediction accuracy

**Expected Skills**:
- ML infrastructure
- Historical trial data

**Expected Output**:
- Trained model
- Feature importance
- Accuracy metrics (AUC, precision, recall)

**Status**: üî¥

---

### Test 8.5: Data Visualization Platform
**Query**: "Design interactive visualization platform for exploring competitive landscape data"

**Tests**:
- Visualization design
- Interactivity features
- Data integration

**Expected Skills**:
- Viz platform design
- UI/UX specification

**Expected Output**:
- Platform mockup
- Feature specifications
- Data schema

**Status**: üî¥

---

### Test 8.6: Collaboration Tools Integration
**Query**: "Integrate competitive intelligence sharing across BD team via Slack/Teams"

**Tests**:
- Collaboration tool integration
- Sharing workflows
- Access control

**Expected Skills**:
- Integration design
- Workflow automation

**Expected Output**:
- Integration specification
- Channel structure
- Sharing protocols

**Status**: üî¥

---

### Test 8.7: Knowledge Management System
**Query**: "Design knowledge management system for historical competitive intelligence tracking"

**Tests**:
- Knowledge base design
- Search functionality
- Version control

**Expected Skills**:
- KMS architecture
- Search design

**Expected Output**:
- System architecture
- Data schema
- Search specifications

**Status**: üî¥

---

### Test 8.8: Predictive Analytics Timeline
**Query**: "Build predictive analytics system for forecasting clinical trial completion dates"

**Tests**:
- Predictive modeling
- Timeline forecasting
- Accuracy tracking

**Expected Skills**:
- Predictive analytics
- Historical data

**Expected Output**:
- Prediction model
- Accuracy metrics
- Confidence intervals

**Status**: üî¥

---

## Category 9: Therapeutic Area Specialization ("The Specialist")

*"Deep expertise in every indication"*

### Test 9.1: Oncology Pipeline Complexity
**Query**: "Analyze complexity of triple combination regimens in non-small cell lung cancer"

**Tests**:
- Combination regimen analysis
- Toxicity profile assessment
- Efficacy prediction

**Expected Skills**:
- New skill: `get_nsclc_triple_combos`
- Combination analysis

**Expected Output**:
- List of triple combos
- Safety/efficacy trade-offs
- Viable regimens

**Status**: üî¥

---

### Test 9.2: Rare Disease Competitive Dynamics
**Query**: "Assess competitive dynamics in spinal muscular atrophy (SMA) with 3 approved therapies"

**Tests**:
- Rare disease market analysis
- Head-to-head comparison
- Market share dynamics

**Expected Skills**:
- New skill: `get_sma_approved_therapies`
- Market dynamics

**Expected Output**:
- Therapy comparison matrix
- Market share estimates
- Switching patterns

**Status**: üî¥

---

### Test 9.3: Cell & Gene Therapy Tracking
**Query**: "Track all CAR-T programs in hematologic malignancies and solid tumors"

**Tests**:
- CAR-T program identification
- Target antigen mapping
- Clinical stage tracking

**Expected Skills**:
- New skill: `get_cart_all_programs`
- Target analysis

**Expected Output**:
- CAR-T program list
- Target antigen distribution
- Liquid vs solid tumor split

**Status**: üî¥

---

### Test 9.4: Neurology Long Timeline Analysis
**Query**: "Model 15-year development timeline for disease-modifying Parkinson's disease therapies"

**Tests**:
- Long-term timeline modeling
- Endpoint challenges
- Patient recruitment

**Expected Skills**:
- New skill: `get_parkinsons_dmt_programs`
- Long-term modeling

**Expected Output**:
- 15-year timeline projections
- Key challenges identified
- Success probability

**Status**: üî¥

---

### Test 9.5: Immunology Market Evolution
**Query**: "Analyze evolution of IL-17 inhibitor market from launch to maturity over 10 years"

**Tests**:
- Market evolution analysis
- Product lifecycle tracking
- Competitive entry impact

**Expected Skills**:
- New skill: `get_il17_inhibitor_history`
- Market evolution modeling

**Expected Output**:
- Timeline of launches
- Market share evolution
- Key inflection points

**Status**: üî¥

---

### Test 9.6: Cardiovascular Outcomes Trials
**Query**: "Track all cardiovascular outcomes trials (CVOTs) for diabetes drugs"

**Tests**:
- CVOT identification
- Safety endpoint tracking
- Regulatory requirements

**Expected Skills**:
- New skill: `get_diabetes_cvots`
- Outcomes trial analysis

**Expected Output**:
- List of CVOTs
- Primary endpoints
- Results timeline

**Status**: üî¥

---

### Test 9.7: Digital Therapeutics Integration
**Query**: "Identify all digital therapeutic programs with FDA regulatory pathway"

**Tests**:
- Digital health program tracking
- Regulatory pathway analysis
- Reimbursement assessment

**Expected Skills**:
- New skill: `get_digital_therapeutics_fda`
- Digital health domain

**Expected Output**:
- Digital therapeutic list
- Regulatory status
- Reimbursement landscape

**Status**: üî¥

---

### Test 9.8: Platform Technology Assessment
**Query**: "Assess Intellia's CRISPR platform competitiveness across indications vs Editas and CRISPR Therapeutics"

**Tests**:
- Platform comparison
- Cross-indication analysis
- Technology maturity

**Expected Skills**:
- New skill: `get_crispr_platform_comparison`
- Technology assessment

**Expected Output**:
- Platform comparison matrix
- Indication pipeline
- Competitive advantages

**Status**: üî¥

---

## Category 10: Partnership & Deal Intelligence ("The Deal Maker")

*"Every deal tells a story"*

### Test 10.1: Licensing Agreement Monitoring
**Query**: "Track all licensing deals in obesity space in 2024 and analyze deal terms"

**Tests**:
- Deal identification
- Term analysis
- Valuation assessment

**Expected Skills**:
- Deal database access
- Term extraction

**Expected Output**:
- List of obesity deals
- Deal structure summary
- Valuation multiples

**Status**: üî¥

---

### Test 10.2: Collaboration Pattern Analysis
**Query**: "Analyze Genentech's collaboration patterns: academic vs biotech vs pharma partnerships"

**Tests**:
- Partnership type classification
- Pattern identification
- Strategic rationale

**Expected Skills**:
- New skill: `get_genentech_partnerships`
- Pattern analysis

**Expected Output**:
- Partnership timeline
- Partner type distribution
- Deal structure patterns

**Status**: üî¥

---

### Test 10.3: Academic Innovation Sourcing
**Query**: "Identify top 10 academic institutions licensing drug candidates to pharma in 2023-2024"

**Tests**:
- Academic deal tracking
- Institution ranking
- Technology areas

**Expected Skills**:
- Academic licensing data
- Institution analysis

**Expected Output**:
- Top 10 institutions
- Deal counts
- Technology focus areas

**Status**: üî¥

---

### Test 10.4: M&A Activity Prediction
**Query**: "Predict M&A targets in rare disease space based on portfolio gaps and company valuations"

**Tests**:
- Gap analysis
- Target screening
- Acquisition probability

**Expected Skills**:
- Portfolio gap analysis
- Valuation screening

**Expected Output**:
- Target company list (top 10)
- Acquisition rationale
- Probability scores

**Status**: üî¥

---

### Test 10.5: Joint Venture Analysis
**Query**: "Analyze Bayer and Merck's joint venture in China and assess strategic benefits"

**Tests**:
- JV structure analysis
- Strategic rationale
- Risk/benefit assessment

**Expected Skills**:
- JV database access
- Strategic analysis

**Expected Output**:
- JV structure description
- Strategic benefits
- Risk factors

**Status**: üî¥

---

### Test 10.6: Technology Transfer Deals
**Query**: "Track all mRNA technology platform licensing deals 2020-2025"

**Tests**:
- Platform deal identification
- Technology transfer terms
- Strategic implications

**Expected Skills**:
- Platform licensing data
- Deal term analysis

**Expected Output**:
- Platform deal list
- License terms (exclusive/non-exclusive)
- Strategic impact

**Status**: üî¥

---

### Test 10.7: Regional Partnership Agreements
**Query**: "Analyze regional commercialization partnerships for China market entry"

**Tests**:
- Regional deal tracking
- Partner selection patterns
- Deal structure analysis

**Expected Skills**:
- China partnership data
- Regional analysis

**Expected Output**:
- China partnership list
- Preferred partners
- Deal structures

**Status**: üî¥

---

### Test 10.8: Deal Value Benchmarking
**Query**: "Benchmark deal values for Phase 2 oncology assets: upfront, milestones, royalties"

**Tests**:
- Deal term extraction
- Value benchmarking
- Market rate analysis

**Expected Skills**:
- Deal database access
- Financial benchmarking

**Expected Output**:
- Benchmark ranges (P25, P50, P75)
- Deal structure norms
- Outlier deals

**Status**: üî¥

---

## Category 11: Risk Assessment & Early Warning ("The Oracle")

*"See the future, avoid the traps"*

### Test 11.1: Competitive Threat Identification
**Query**: "Identify top 5 competitive threats to Humira biosimilars in immunology"

**Tests**:
- Threat identification
- Severity scoring
- Impact assessment

**Expected Skills**:
- New skill: `get_humira_biosimilar_competitors`
- Threat analysis

**Expected Output**:
- Top 5 threats
- Severity scores (1-10)
- Mitigation strategies

**Status**: üî¥

---

### Test 11.2: Pipeline Failure Impact
**Query**: "Assess impact of Eli Lilly's Alzheimer's program failure on competitive landscape"

**Tests**:
- Failure impact modeling
- Competitive response prediction
- Market dynamics shift

**Expected Skills**:
- Failure analysis framework
- Market dynamics

**Expected Output**:
- Market share redistribution
- Competitor responses
- Strategic implications

**Status**: üî¥

---

### Test 11.3: Regulatory Setback Monitoring
**Query**: "Monitor all FDA clinical holds in gene therapy and assess category-wide implications"

**Tests**:
- Clinical hold tracking
- Safety signal analysis
- Regulatory impact

**Expected Skills**:
- New skill: `get_gene_therapy_clinical_holds`
- Safety analysis

**Expected Output**:
- List of clinical holds
- Common safety signals
- Regulatory guidance changes

**Status**: üî¥

---

### Test 11.4: Safety Signal Detection
**Query**: "Detect emerging safety signals across all BTK inhibitors and assess competitive vulnerability"

**Tests**:
- Adverse event monitoring
- Signal detection
- Competitive impact

**Expected Skills**:
- New skill: `get_btk_inhibitor_safety`
- FDA FAERS data

**Expected Output**:
- Safety signal summary
- Affected drugs
- Competitive implications

**Status**: üî¥

---

### Test 11.5: Patent Challenge Tracking
**Query**: "Track all ANDA filings challenging Keytruda patents and assess biosimilar entry risk"

**Tests**:
- Patent litigation tracking
- ANDA filing monitoring
- Entry timeline prediction

**Expected Skills**:
- Patent database access
- Litigation tracking

**Expected Output**:
- ANDA filing list
- Patent challenge status
- Biosimilar entry dates

**Status**: üî¥

---

### Test 11.6: Technology Substitution Risk
**Query**: "Assess risk of CRISPR gene editing displacing viral vector gene therapy"

**Tests**:
- Technology substitution analysis
- Adoption curve prediction
- Market disruption modeling

**Expected Skills**:
- Technology analysis
- Disruption modeling

**Expected Output**:
- Substitution probability
- Timeline estimate
- Affected products

**Status**: üî¥

---

### Test 11.7: Biosimilar Entry Timeline
**Query**: "Predict biosimilar entry timeline for Stelara and assess revenue erosion"

**Tests**:
- Biosimilar entry prediction
- Revenue erosion modeling
- Market share impact

**Expected Skills**:
- Biosimilar pipeline tracking
- Erosion modeling

**Expected Output**:
- Entry date predictions
- Revenue impact (year 1-5)
- Market share erosion

**Status**: üî¥

---

### Test 11.8: Reimbursement Barrier Analysis
**Query**: "Identify reimbursement barriers for cell therapy in EU markets and assess commercial risk"

**Tests**:
- Payer policy analysis
- Access barrier identification
- Commercial impact

**Expected Skills**:
- Payer policy database
- Access analysis

**Expected Output**:
- Barrier identification
- Country-specific challenges
- Revenue impact

**Status**: üî¥

---

## Category 12: Action Planning & Recommendations ("The General")

*"Strategy without execution is hallucination"*

### Test 12.1: Acceleration Opportunity Identification
**Query**: "Identify opportunities to accelerate internal diabetes program based on competitor delays"

**Tests**:
- Competitive gap analysis
- Acceleration feasibility
- Timeline optimization

**Expected Skills**:
- Competitive timeline tracking
- Acceleration assessment

**Expected Output**:
- Acceleration opportunities
- Timeline impact
- Resource requirements

**Status**: üî¥

---

### Test 12.2: Acquisition Target Prioritization
**Query**: "Prioritize top 10 acquisition targets in neurology based on strategic fit, valuation, and competitive urgency"

**Tests**:
- Target screening
- Multi-criteria scoring
- Prioritization framework

**Expected Skills**:
- Target identification
- Scoring framework

**Expected Output**:
- Ranked target list (1-10)
- Score breakdown
- Deal rationale

**Status**: üî¥

---

### Test 12.3: Partnership Strategy Recommendations
**Query**: "Recommend partnership strategy for entering CAR-T market: internal build vs acquire vs license"

**Tests**:
- Build-buy-partner analysis
- Option comparison
- Strategic recommendation

**Expected Skills**:
- Strategic framework
- Market analysis

**Expected Output**:
- Option comparison matrix
- Recommended strategy
- Implementation plan

**Status**: üî¥

---

### Test 12.4: Development Strategy Adjustments
**Query**: "Recommend development strategy adjustments for Phase 2 program based on competitor Phase 3 failures"

**Tests**:
- Competitor failure analysis
- Strategy adjustment
- Risk mitigation

**Expected Skills**:
- Failure analysis
- Strategy framework

**Expected Output**:
- Recommended adjustments
- Risk mitigation strategies
- Success probability impact

**Status**: üî¥

---

### Test 12.5: Investment Prioritization
**Query**: "Prioritize R&D investment across 5 therapeutic areas to maintain competitive position"

**Tests**:
- Portfolio optimization
- Investment allocation
- Competitive positioning

**Expected Skills**:
- Portfolio analysis
- Investment modeling

**Expected Output**:
- Recommended allocation
- ROI projections
- Competitive impact

**Status**: üî¥

---

### Test 12.6: Market Entry Timing Optimization
**Query**: "Optimize market entry timing for biosimilar relative to 3 competitor launches"

**Tests**:
- Launch timing modeling
- Competitive response prediction
- Revenue optimization

**Expected Skills**:
- Launch modeling
- Competitive dynamics

**Expected Output**:
- Optimal launch date
- Revenue scenarios
- Competitive responses

**Status**: üî¥

---

### Test 12.7: Defensive Strategy Development
**Query**: "Develop defensive strategy for patent expiry of blockbuster drug Enbrel"

**Tests**:
- Defensive strategy design
- Lifecycle management
- Biosimilar competition

**Expected Skills**:
- Lifecycle strategy
- Competitive defense

**Expected Output**:
- Defensive strategy (3-5 tactics)
- Timeline
- Revenue protection estimates

**Status**: üî¥

---

### Test 12.8: Portfolio Optimization
**Query**: "Optimize portfolio by recommending 3 programs to accelerate, 2 to pause, and 2 to terminate based on competitive landscape"

**Tests**:
- Portfolio review
- Go/no-go decisions
- Resource reallocation

**Expected Skills**:
- Portfolio analysis
- Decision framework

**Expected Output**:
- Portfolio recommendations (7 total)
- Rationale for each
- Resource reallocation plan

**Status**: üî¥

---

## Quick Reference: Query Templates

### Basic Template
```
"[Action] [Therapeutic Area] [Aspect] [Filters]"

Examples:
- "Track all KRAS inhibitor Phase 3 trials"
- "Analyze Pfizer's oncology R&D spending"
- "Predict biosimilar entry for Humira"
```

### Complex Template
```
"[Strategic Goal] based on [Data Sources] considering [Constraints]"

Examples:
- "Recommend partnership strategy for CAR-T based on competitor pipelines considering $500M budget"
- "Optimize portfolio allocation across 5 TAs based on competitive landscape considering 3-year horizon"
```

### Comparative Template
```
"Compare [Entity 1] vs [Entity 2] on [Dimensions]"

Examples:
- "Compare Merck vs Pfizer oncology pipelines on speed to market"
- "Compare biosimilar vs originator pricing strategies in immunology"
```

---

## Test Execution Guidelines

### Priority Levels
- **P0 (Critical)**: Core competitive intelligence capabilities - Must pass
- **P1 (High)**: Strategic analysis capabilities - Should pass
- **P2 (Medium)**: Advanced features - Nice to have
- **P3 (Low)**: Future enhancements - Aspirational

### Test Execution Order
1. Start with Category 1 (Pipeline Intelligence) - Foundation
2. Category 4 (Strategic Synthesis) - Core value
3. Category 7 (Reporting) - User-facing output
4. Remaining categories in any order

### Success Criteria
- ‚úÖ **Pass**: Agent delivers accurate, actionable analysis with proper report structure
- ‚ö†Ô∏è **Partial**: Agent delivers analysis but missing key elements (recommendations, data sources, etc.)
- ‚ùå **Fail**: Agent cannot complete task or delivers incorrect analysis

---

## Execution Log Template

When running tests, use this format:

```markdown
## Test Execution: [Test ID] - [Test Name]

**Date**: YYYY-MM-DD
**Executed By**: [Name]
**Agent Version**: [Version]

### Test Query
"[Exact query used]"

### Expected Outcome
- [Expected skill 1]
- [Expected skill 2]
- [Expected output format]

### Actual Outcome
- Skills created: [list]
- Output format: [description]
- Report quality: [assessment]

### Issues Identified
1. [Issue 1]
2. [Issue 2]

### Status: [üî¥|üü°|üü¢|‚ùå]

### Notes
[Any additional observations]
```

---

## Summary Statistics

**Total Test Suite**:
- 12 Categories
- 97 Individual Tests (added pagination test)
- 68 existing skills can be reused
- ~29 new skills will be created
- 6 competitive landscape reports already generated

**Coverage**:
- ‚úÖ All 11 capability domains from agent definition
- ‚úÖ All 12 MCP data sources (all operational)
- ‚úÖ All report template sections
- ‚úÖ Basic to advanced complexity
- ‚úÖ Single-source to multi-source synthesis
- ‚úÖ International patent coverage (90M+ patents, 11 countries)
- ‚úÖ Large-scale data retrieval (pagination support)

**Memorability Devices**:
1. **The Prospector** - Digging for pipeline gold
2. **The Hawk** - Eyes on every trial
3. **The Banker** - Follow the money
4. **The Chess Master** - 3 moves ahead
5. **The Librarian** - Every source cataloged
6. **The Mathematician** - Data into insights
7. **The Journalist** - Story of competition
8. **The Engineer** - Automate everything
9. **The Specialist** - Deep TA expertise
10. **The Deal Maker** - Every deal matters
11. **The Oracle** - See the future
12. **The General** - Strategy to execution

---

**Ready to Execute**: This test suite provides comprehensive coverage of the competitive-landscape-analyst's 100+ capabilities in a memorable, structured format. Each test is actionable and maps to specific skills and expected outputs.
